NEUROSENSE THERAPEUTICS LTD
NASDAQ: NRSN (NeuroSense Therapeutics Ltd.)
Kemas kini terakhir: 12 jam lalu6.35
-0.37 (-5.51%)
| Penutupan Terdahulu | 6.72 |
| Jumlah Dagangan | 7,323 |
| Harga / Buku (P/B) | 2.64 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -0.540 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.83% |
| Nisbah Semasa (MRQ) | 2.21 |
| Aliran Tunai Operasi (OCF TTM) | -10.13 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -7.83 M |
| Pulangan Atas Aset (ROA TTM) | -159.50% |
| Pulangan Atas Ekuiti (ROE TTM) | -2,478.15% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | NeuroSense Therapeutics Ltd. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 1.17 |
|
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 30.98% |
| % Dimiliki oleh Institusi | 0.81% |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |